A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.
Year: 2009
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Irene M Ghobrial, Morie A Gertz, Betsy LaPlant, John Camoriano, Suzanne R. Hayman, Martha Q. Lacy, Stacey Chuma, Patricia Sheehy, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M Ansell, Daniel J DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig B. Reeder, Kenneth C. Anderson, Paul Richardson, Steven Treon, Thomas E Witzig
Institutions: Dana-Farber Cancer Institute, Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2551061425